Example of Using Pharmacogenetics for Drug Safety: Prevalence of the Cyp2c19*2 Polymorphism and Clopidogrel Resistance in Moroccan Population

被引：0
作者：
Lamzouri, A. [1 ]
Laarabi, F. Z. [2 ]
Lyahyai, J. [3 ]
Adadi, N. [2 ,3 ]
El Rherbi, A. [1 ]
Tebaa, A. [1 ]
Bencheikh, R. Soulaymani [1 ]
Sefiani, A. [2 ,3 ]
机构：
[1] Moroccan Anti Poison & Pharmacovigilance Ctr, Pharmacol, Rabat, Morocco
[2] Natl Inst Hlth, Med Genet, Rabat, Morocco
[3] Mohammed V Univ, Human Genom Ctr, Fac Med & Pharm, Rabat, Morocco
来源：
DRUG SAFETY | 2018年 / 41卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
ISoP18-118
引用
收藏
页码：1173 / 1174
页数：2
相关论文
共 4 条
  • [1] Cardiovascular Pharmacogenomics: The Future of Cardiovascular Therapeutics?
    Roden, Dan M.
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2013, 29 (01) : 58 - 66
  • [2] The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study
    Saydam, Faruk
    Degirmenci, Irfan
    Birdane, Alparslan
    Ozdemir, Mahmut
    Ulus, Taner
    Ozbayer, Cansu
    Colak, Ertugrul
    Ata, Necmi
    Gunes, Hasan Veysi
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 (01) : 29 - 36
  • [3] Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
    Scott, S. A.
    Sangkuhl, K.
    Stein, C. M.
    Hulot, J-S
    Mega, J. L.
    Roden, D. M.
    Klein, T. E.
    Sabatine, M. S.
    Johnson, J. A.
    Shuldiner, A. R.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (03) : 317 - 323
  • [4] Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects
    Simon, T.
    Bhatt, D. L.
    Bergougnan, L.
    Farenc, C.
    Pearson, K.
    Perrin, L.
    Vicaut, E.
    LaCreta, F.
    Hurbin, F.
    Dubar, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (02) : 287 - 295
1